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Summary: Enzymological alterations in functional disturbances and in diseases of the intestine are reviewed. Examples
are given for diagnostic significance (e.g. in Hirschsprung's and Crohn's diseases), for pathogenetic considerations (e.g.
in hypolactasia and in celiac disease), and for secondary involvement of the liver (e.g. in intestinal tumors and after
bypass surgery) and are discussed in more detail.
Klinische Aspekte der Enzymologie des Darms
Zusammenfassung: Enzymologische Veränderungen bei Funktions-Störungen und Erkrankungen des Darmes werden
anhand der neueren Literatur dargestellt und an einzelnen Krankheitsbildern näher beschrieben: diagnostische Be-
deutung (z.B. beim M. Hirschsprung und M. Crohri), pathogenetische Aspekte (z.B. bei der Hypolactasie und der Coe-
liakie), sowie Folgeerscheinungen an der Leber (z.B. bei Darm-Tumoren und nach Bypass-Operationen) werden be-
sprochen.
introduction
When discussing the pathology of intestinal enzymes, it is
commonplace to begin with the enzyme deficiencies,
although they are actually rather rare disorders. For the
clinician, they are less important than the ordinary bowel
diseases and their enzymological aspects.
Constipation
In temperate industrialized countries, constipation is the
most common disorder of the gut in the adult. Unfor-
tunately, as a rule, neither morphological nor biochemical
findings correlate with the impaired bowel motility. More
often than not, it must be attributed to dietary and
emptying habits or to psychosomatic origins.
There is, however, one important exception, well known to
the pediatrician: Hirschsprung*s disease, Its diagnosis relies
on radiology, manometry and essentially on the absence
of ganglion cells in biopsies of rectal submücosa, which is
difficult to demonstrate. The discovery of an increased
acetylcholinesterase activity in rectal tissue contributed
a great deal more precision to the diagnosis. Initially,
histochernical detection was employed (1,2,3), the
results being somewhat subjective and, at best, semi-
quantitative (4). A more accurate biochemical method,
measured in homogenate, was introduced by Boston et
al. in 1975 (5) and was improved by the use of a selec-
tive inhibitor of non-specific cholinesterases (6). Acetyl-
cholinesterase, expressed as fraction of total cholin-
esterase is about twice as high in biopsies obtained from
patients with Hirschsprung's disease than in normal
rectal biopsies. Figure 1 shows that the borderline lies
between 0.60 and 0.70 and that there is no overlap.
Recently, Boston et al. found a similar difference in
serum and in red blood cells, but here the overlap is
considerable. This is, nonetheless, an interesting sign of
the systemic effects of Hirschsprung's disease (7).
*) Partly presented as Invited Lecture at the 2nd Meeting of the
International {Society for Clinical Enzymology, 25;2.-2.3.1979,
San Diego, Cal. USA.
In children, in warm climates, and in developing countries,
diarrhea is more common than constipation. In addition,
episodes of4oose stools alternating with constipation
belong to the irritable bowel syndrome in the adult.
The various causes of acute and chronic diarrhea can thus
be grouped primarily as infectious and presumably non-
infectious, and the latter further into socalled functional
diarrhea, which is used synonymous to psychogenic, and
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Fig. 1. Acetylcholinesterase as fraction of total cholinesterase
activity (from Dale et al. (6)).
the primary metabolic type, which is due to a deficiency
or insufficiency in digestion or absorption. Differential
diagnosis between these basically different etiologies is
not as easy as might be imagined.
Table 1 demonstrates that the main abdominal symptoms
are virtually the same in lactose intolerance and in the
irritable colon syndrome (8). Thus, it is not too sur-
prising to find, among patients with non-specific ab:
dominal complaints, some with metabolic disturbances,
which are often falsely diagnosed for years (ta]ble 2;
8,9,10). In this group, hypolactasia is naturally the most
Tab. 1. Incidence of abdominal symptoms in patients with un-
specific abdominal complaints (from Jussila et al. (8)).
Jejunal lactase activity >1.5U/g <1.5U/g
(n = 29) (n = 12)
Abdominal fullness
Meteprism
Nausea
Unidentified abdominal complaints
Loose stools
Watery diarrhea
Obstipation
100%
76%
55%
45%
38%
14%
17%
92%
83%
50%
42%
42%
25%
8%
Tab. 2. Lactase activity in jejunal biopsies of patients with
irritable colon syndrome (from Weser et ai. (9)).
n Lactase , .Saccharase
(U/g protein) (U/g protein)
Patients with irritable gut
and normal lactose tolerance 6 34.0 ± 11.9 45.1 ± 22.8
Patients with irritable gut
and abnormal lactose tolerance 1 4 3.9 ± 3.1 39.6 ± 11.5
Patients with untreated
celiac disease 9 2.9 ± 1.7 21.8 ± 15.0
Asymptomatic controls 5 49.6 ± 17.5 67.3 ± 24.6
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Fig. 2. Mean disaccharid se activities and saccharase - to-
lactase (S/L) and maltase-to-lactase (M/L) ratios
in one normal subject on glucose (white columns)
and fructose (hatched columns) diets. The standard error
of the mean is in brackets. From Rosensweig (16).
common event, ranging from 30-50 % (8,9). True
deficiencies, however, which should also be considered
are fructose malabsorption (10), saccharose-isomaltose
malabsorption (11,12,13), glucose-galactose malab-
sorption (14,15) and other even rarer deficiencies. The
importance of their detection lies in the therapeutical
consequences: long-standing diarrhea and abdominal
distress can be cured within days by a diet which avoids
the malabsorbed carbohydrate or induces the defective
enzyme without adverse side-effects, as e.g. the non-
substrate fructose does in incomplete saccharase defi-
ciency (fig. 2; 16,17).
Not only brush border enzymes such as the disacchari-
dases, but also cytosolic enzymes of intermediary
carbohydrate metabolism, adapt to dietary sugars. Folate
plays a role in this regulation, which is still poorly urider-
§tood, and, besides the overall adaptation to a carbo-
hydrate-rich diet, specific reactions of single enzymes to
individual sugars occur. When these essential regulatory
processes are disturbed, similar symptoms as in mal-
absorption of sugars ensue. Such observations led
Rosensweig and his group to the concept of the "mal-
adaptation syndrome" in cases of carbohydrate-sen-
sitive diarrhea without overt enzyme deficiency or any
other gastro-intestinal disorder (16,18).
Some remarks on hypolactasia, which is a more adequate
term than lactase deficiency for the denotation of the
normal developmental pattern in mammals, the decrease
of lactase after weaning: in the human, hypolactasia is
also the "wild type" in genetic language, and the pre-
vailing condition of adult age in most populations.
Table 3 shows that persistent lactase activity is common
in Northern and Central Europe and in the white
population of North America and Australia, particularly
in their fair-complexioned part. Persistent lactase
activity is very rare or absent in most Mongolian popul·
ations, including Indians and Eskimos, in tropical
Africa and in the Melanesian peoples. With few ex-
ceptions, it is rare in the Middle East. In between, there
is a broad zone in Southern Europe with 30-70 %
persistent lactase activity (19):
J. Clin. Chem. Clin. Biochem. / Vol. 17,1979 / No. 11
Schmidt and Schmidt: Clinical aspects of gut enzymology 695
Tab. 3. Geographical distribution of lactase phenotypes and persistent lactase activity (PLA) gene frequency (from Flatz & Rotihauwe
(19)).
Country
or region
Sweden
Denmark
Germany
Spain
CSSR
Greece
Pakistan
India
Israel
Lebanon
Thailand
USA
Alaska
Surinam
Group
or location
Patients
Patients
—
-
Czechs
Greeks
—Delhi
—Arabs
North
Whites
Indians
Negroes
Eskimos
—
Number
examined
700
155
67
267
104
700
55
70
93
151
149
771
75
349
36
60
Number
of absorbers
679
139
59
209
76
371
52
50
56
32
0
592
26
76
6
0
Number
of malabsorbers
21
16
8
58
28
329
3
20
57
119
149
179
49
273
30
60
Frequency
of PLA gene
0.827
0.679
0.654
0.534
0.481
0.341
0.766
0.465
0.217
0.112
0
0.518
0.192
0.116
0.087
0
Origin and significance of persistent lactase activity are
still under discussion. The persistent lactase activity gene
must certainly have emerged by mutation and spread as a
consequence of a selective advantage. The cultural
historic hypothesis (20, 21) states that after the domes-
tication of milking animals in the Neolithic age, some
population groups learned to ferment milk, while others
did not, and developed persistent lactase activity. This
theory probably fits small groups of nomads under ex-
treme conditions. The map of the world, however, shows
no parallelism between milk drinkers and persistent
lactase activity. This, and elaborate calculations of Cavalli-
Sforza (22), rule out dairy farming as a general cause of
lactase persistence.
There must then be a selective advantage for the lactose
absorber in higher latitudes: Flatz ScRotthauwe put
forward a hypothesis (23) that, due to its promotion
of calcium absorption, lactose can replace vitamin D in
restoring calcium balance in rickets (24,25), and
analogous to the depigmentation of the Northern Euro-
peans, good lactose absorption would prevent rickets,
particularly pelvis deformation in young women, and
could thus favor the propagation of individuals with
persistent lactase activity in environments with low UV
irradiation and poor dietary supply of vitamin D (26,27).
This theory is also not unchallenged (28, 29), and many
other more practical problems are still open concerning
the two lactase phenotypes: aside from the question of
the usefulness of "milk programs" in countries with a
Wgh incidence of non-absorbers and in milky diets for
nutritional restoration in general, primary hypolactasia
frequently interferes with the diagnostic procedure in
secondary disaecharidase deficiencies, which are very
common and arise from a wide variety of causes.
This can be demonstrated by comparing disaecharidase
activity in jejunal biopsies from black and Caucasian
american alcoholics: in the former group with the high
Tab. 4. Symptomatic intestinal disaecharidase deficiency in
alcoholics (from Perlow et al. (30)).
Lactase activity Saccharase
activity
< lU/g <6U/g
White controls
White alcoholics
Black controls
Black alcoholics
0/7 0/6
2/12 2/8
5/10 0/7
11/11 3/7
rate of non-absorbers, the alcohol-induced mucosal
atrophy apparently leads to lactase deficiency in all cases,
but only in 3 cases to a parallel decrease in saccharase
activity, whereas in the white group the alterations of
both enzymes correlate well (table 4; 30). The correl-
ation between the diminution of brush border enzymes,
such as disaccharidases and oligopeptidases and of cyto-
solic enzymes, such as dipeptidases and their respective
amount in normal enterocytes on the one hand, and the
degree of mucosal atrophy on the other, as is shown in
figure 3, holds also true for lactase, but only in popula-
tions with a high prevalence of persistent lactase activity
(31,32,32a).
Celiac disease is a good example both of this parallelism
and of the reversibility of the pathological changes with
adequate dietary therapy (table 5; 33,34). The diminution
of brush border enzymes precedes the respective alter-
ations of the cytosolic enzymes, which may not be
marked until mucosal atrophy is total (fig. 4; 33,34,35).
Meanwhile there is a considerable increase of lysosomal
enzymes in mucosal tissue, which has for reasons of
quantity been attributed to the enterocytes themselves,
not to the infiltrating round cells, and which is com-
bined with an augmented lysosomal fragility (fig. 5;
36,37).
After gluten withdrawal from the diet, nearly all
the enzymes return to normal and the stability of the
J. Clin. Chem. Clin. Biochem. / Vol. 17,1979 / No. 11
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subcellular organelles improves. Only the defectiveness
of the brush border enzymes persists, despite the quite
normal morphology found after 2-10 years of treat-
ment (37), Phlorizin hydrolase, a brush border β-
glucosidase, in particular remains very low or absent.
This has led to consideration of an etiolpgical role of
this enzyme in glutensensitive enteropathy; the more
so since a carbohydrate component of gliadine is
probably the noxious part of wheat flour which cannot
be degraded and binds to the brush border as the primary
site of impact (38,39,40,41).
Rather unaffected in celiac disease remains the entero-
kinase (table 6; 42,43). This and other evidence has led
to the conclusion that entefokinase is not a brush border
enzyme but a secretory enzyme which originates in the
Brunner glands or the goblet cells (44,45,46,47), which
are scarcely involved in the atrophy in celiac disease.
There are, however, conditions with subtotal reduction
of enterokinase activity in duodenal mucosa with grade
III atrophy, clinically appearing as intractable diarrhea of
infancy (45,49,50). Figure 6 demonstrates the difference
Tab. 5. Reversibility of the pathological changes in the disaccharidase activities (χ ± SD) with adequate dietary therapy (fiomMalis et
al. (33)).
Adults No. Saccharase Maltase Trehalase Lactase Cello biase
(U/g protein) (U/g protein) (U/g protein) (U/g protein) (U/g protein)
Control group
Celiac sprue
-relapse
-remission
Children
15
9
14
148.0 ± 10.5 443.0 ± 44.9 33.3 ± 3.5 48.4 ± 5.2
13.3 ± 4.9 37.3 ± 11.2 0.5 ± 0.2 l".5 ± 0.9
59.2 ±18.8 177.0 ± 38.0 14.6 ± 3.3 15.1 ± 3.8
12.6 ± 1.3
0.7 ± 0.3
3.2 ±1.6
Control group
Celiac sprue
-relapse
-remission
Mucoviscidosis
17
27
25
8
176.8 ± 25.9
22.8 ± 3.7
87.0 ± 15.1
119.5± 40.0
524.5 ± 81.0
62.9 ± 6.9
221 .0± 40.5
332.4 ±130.0
28.5 ± 4.9
1.0 ±0.2
10.9 ± 3.3
7.5 ± 2.5
48.8 ± 6.8
1.6 ±0.6
15,9 ± 3.6
28.5 ± 8.2
15.2 ± 2.7
0.6 ± 0.2
5.1 ± 1.0
7.6 ±-2.2
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Tab. 6. Enterbkinase activity in various diseases of the intestine
(from Niessen et al. (44)).
No. of Enterokinase activity
biop-
sies Mucosal Intraluminal
Control, normal
mucosa 59
Chronic nonspecific
diarrhea
Atrophy grade I 30
Atrophy grade II 14
Milk protein allergy 6
Hypoproteinemia
Intestinal lymphan- 4
giectasia
Lymphoid nodular
hyperplasia 3
Saccharase-isomaltase
deficiency 3
Low tryptic activity
Cystic fibrosis 9
Shwachmajv-diamond
syndrome 3
Congenital enterokinase
deficiency 2
109.0 ± 34.2
61.7 ± 44.2
44.4 ± 27.0
77.7 ±55.0
79.1 ± 35.5
83.2 ±23.3
105.6 ±23.3
92.8 ± 38.0
91.9 ±18.6
0
18.6 ±8.8
12.9 ± 3.7 -
10.6 ± 5.7
12.5 ± 2.0
13.4 ±0.9
12.3 ±0.4
18.2 ± 1.3
87.6 ± 30.3
30.0 ± 8.3
0
between celiac disease and intractable diarrhea with
respect to enterokinase and the similarity with respect to
the disaccharid ses. Thus, a pathogenetic role of entero-
kinase has been discussed, related possibly to a reduced
number of goblet cells or to the effect of impaired out-
put of bile acids or as primary enterokinase deficiency
(44,45,48,51).
On the whole, there are still many inconsistencies in the
findings of different authors in non-infectious diarrheal
disorders, particularly with regard to etiological factors
and immunological processes (52,53,54). The clinical and
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the enzymological picture becomes even more complic-
ated by the intestinal sequelae of exocrine pancreatic
insufficiency.
In infancy, cystic fibrosis, and in adult age, the various
types of chronic pancreatitis must be differentiated from
primary enteropathies. As long as the intestinal mucosa
J. Clin. Chem. Clin. Biochem. / Vol. 17,1979 / No. 11
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Fig. 7. Comparison of the disaccharidase activities in patients
with cystic fibrosis (hatched columns) and in control sub-
jects (white columns) with normal morphology. Upper
part of figure represents groups under 5 years of age
(134 controls, 21 patients) and lower part, groups above
5 years of age (43 controls, 15 patients). From Arvantakis
6 Olsen (56). Vertical lines represent ± SEM.
is not involved, chronic pancreatic insufficiency leads
to elevated instead of decreased activities of brush border
enzymes, suggesting delayed proteolytic degradation
(fig. 7; 33,55,56,57).
Inflammatory Disorders
The disturbance of lactose absorption in acute enteritis is
long known. It is due to a transient villous atrophy with
low disaccharidase, particularly lactase, activity. The
evidence that lactase is the enzyme most vulnerable in
gastrointestinal infections and in malnutrition (58,59,60,
61) has led to the hypothesis of lactose intolerance in
tropical countries as being secondary to mucosal damage
in childhood (62,63). This was later rejected by other
investigators (16,19). It is, however, understandable that
chronic inflammatory bowel disease, such as ulcerative
colitis and Cro/w's disease, also have reduced activities of
disaccharidases, at least during acute stages (64,65,66).
The etiology and pathogenesis of ulcerative colitis and
Crohrfs disease are still obscure and the differential
diagnosis between them often difficult. Since Crohn's
disease is a granulomatous inflammation, several en-
zymes known to be elevated in other granulomatous
diseases have been tested in this respect. Collagen peptid-
ase was found to be elevated in serum in regional entero^
colitis (fig. 8; 67). Its activity has been found higher in
more severely ill patients, and lower under immuno^
suppressive treatment. It is likewise elevated, however, in
rectal mucosa of patients with ulcerative colitis (68).
Thus, it is probably only a non-specific marker of in-
flammatory processes.
Glucosamine synthetase, a possibly rate-limiting enzyme
of glycoprotein synthesis, has been measured in colonic
biopsies from patients with ulcerative and membranous
colitis and with Crohn's disease (69,70). It was found to
be correlated to the density of enterocytes and was
thought to be indicative of the healing capacity of the
mucosa. No difference was found among the 3 disorders.
Recently, a highly significant increase of prolyl hydroxy-
lase in rectal mucosa of patients with Crohrfs disease,
but not with ulcerative colitis, has been reported by
Farthing et al. (71). The 3-fold increase of this enzyme
of collagen metabolism in the unaffected rectal mucosa
of Crohn patients provides further evidence for the
diffuse nature of regional enterpcolitis. However, whether
this enzyme can serve for differential diagnosis should be
judged with caution: There is a broad overlap, and the
experience with the determination of lysozyme, initiated
with such great expectations, might be a warning. The
suggestion by Falchuk et aL that differential diagnosis
of inflammatory bowel diseases is possible by the deter-
mination of lysozyme in serum (72), has, to date, not
produced convincing results, despite world-wide endea-
vors (73-80), as summarized in table 7. This seems not
only to be a methodological problem (81), but the natural
consequence of the non-specificity of lysozyme elevation.
J, Clin. Chem. Clin. Biochem. / Vol. 17,1979 / No. 11
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Tab. 7. Lysozyme in serum (mg/1) in inflammatory bowel diseases
A = Agar plate method, T = Turbidimetric method
Author(s)
Falchuk et al.
(72)
Pruzanski &
Mar con (73)
Peeters et al.
(74)
Nugent et al.
(75)
Farak (76)
R llinghoffet
al. (77)
Klass&Neale
(78)
El-Khatib et al.
(79)
Goesmann et
al. (80) un-
published)
Method Controls
A
A
T
T
A
T
A
A
T
A
T
8.8 ±
9.7 ±
17.5 ±
7.0 ±
5.14
4.81
8.4 ±
27 .4 ±
4.4 ±
6.0 ±
15.6 ±
0.
1.
3
8
3.4
2.0
1.
17
2
1
2.
8
.5
.0
.5
0
O-oJw's
Disease
26.3 ±
8.3 ±
20.5 ±
10.0 ±
7.17
5.00
8.1 ±
60.1 ±
9.2 ±
10.5 ±
20.8 ±
1.4
2
7
4
3
30
.3
.1
.0
.0
.7
2.7
6
5
.8
.2
Ulcerative
Colitis
9.3
7.7
17.6
7.0
5.14
4.90
8.6
30.5
7.3
9.6
19.1
±
±
±
±
±
±
±
±
±
0.
1.
5.
2.
2.
17.
5.
4.
4.
6
6
6
0
9
1
1
1
0
As the enzyme originates in the phagocytic cells of the
inflamed tissue (82,83), its activity in serum depends
more on the severity of the process than on any other
factor. However, in view of the broad overlap even between
carefully defined and selected groups, lysozyme is helpful
neither in differential diagnosis nor in follow-up.
The liver receives first hand most material which is ab-
sorbed and metabolized by the gut. It serves as a filter
which protects the rest of the system. Thus, liver in-
volvement must be expected to occur with any appreciable
intestinal cell damage, despite the fact that much of the
debris is released into the lumen. The reports on this
subject, however, are contradictory. Excluding acute viral
hepatitis, the incidence of liver involvement in ulcerative
colitis and regional enterocolitis is given between 1.3 %
(84) and 4.8 % (85) up to more than 70 % (87,88,89) and
89% (86). Bade and his group have put forward the hypo-
thesis of portal bacteremia as chief cause of secondary
liver damage. However, they could not establish a good
correlation (90).
Thus, clinical enzymology has not achieved a great deal
to date in inflammatory bowel disease, including even
the interesting findings of atypical alkaline phosphatases
in serum (91,92) or acid hydrolases in monocytes (93)
reported by British investigators. Our own promising
results with respect to the correlation between cholin-
esterase activity and severity of the illness will be published
elsewhere.
Tumors of the Large Bowel
Colorectal cancers take first or second place among
malignancies in many temperate countries. At present
50 % of the patients are cured surgically. For the re-
maining half an earlier diagnosis must be effected.
Enzymatic diagnoses of tumors rely basically on
marked differences in enzyme patterns between normal
and malignant tissue, which can be reflected in serum.
Baer and his associates have evaluated a large pattern of
enzymes in colon mucosa and carcinoma (94). Their
findings have been confirmed and extended by Dale
(95) and Shonk et al (96). Table 8 shows the features of
colon cancer as compared to normal mucosa for some
selected enzymes: very low activity of enzymes with
special functions, low values of enzymes which are
connected with the citric acid cycle, unchanged bi-
directional enzymes of carbohydrate metabolism and
higher than normal glycolytic and hexose monophos-
phate pathway enzymes are characteristic. The enzyme
pattern behaves similarly as has been shown by Weber
for hepatomas (97) and by ourselves to a lesser degree
for inflammatory liver diseases (94,98). The alterations
are not marked enough to yield significant changes in
serum.
In colon cancer tissue, changes of the lactate dehydro-
genase isoenzyme pattern towards the muscle type or
Tab. 8. Enzyme activities (U/g protein) in human colon mucosa and colon carcinoma (from Baer et al. (94)).
Normal mucosa Adenocarcinoma Carcinoma/
normal
Alanine aminotransf erase (2.6.L2)
Alcohol dehydrogenase (1.1.1.1)
Glycerol-S^phosphate dehydrogenase (NAD+) (1.1.1.8)
Aspartate aminotransferase (2.6.1.1)
Glutamate dehydrogenase (NAD(P)+) (1.4.1.3)
Isoeittate defcydrogenase (NAD?*) (1.1.1-42)
Malate dehydrogenase (1.1.1.37)
Phosphoglycerate kin se (2.7.2.3)
Enplase (4.2,1.1)
Pyruvate kinase (2.7.1.40)
Glucose-6-phosphate dehydrogenase (1.1.1.44)
Lactate dehydrogenase (1.1.1.27)
Fiuctpse-bisphosphate aldolase (4.1 .2.1 3)
29
33
31
305
164
367
2671
1103
01 5jiij
501
ΛΛ20
1299
64
1
5
10
109
61
212
1811
1119
710ftfAJ
745
1·^32
2615
1 29
0.03
0.15
0.32
0.36
0.37
0.58
0.68
l.Ol
ι 09l.U.£
1.49
1 £f\.oU
2.01
2.02
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the mid-fractions have been found (94,99). This has
also been observed in normal mucosa near the tumor
(101) and in precancerous lesions of ulcerative colitis
(100). In serum, however, there is no reliable reflection
of these changes.
Another approach to a timely diagnosis is based on the
deletion of some normal mucosal antigens and the
appearance of new cancer-associated ones which have
been observed in various human tumors and in serum.
The latter are thought to be incomplete antigens, and
the underlying enzyme deficiencies have been searched
for. The results of these endeavors are rather confusing:
Some presumably membrane-bound glycosyl trans-
ferases have been reported to be reduced, particularly in
the presence of exogenous acceptors like CEA (table 9:
102,103). Others have been found increased and acceptor-
sensitive in tumor tissue and elevated in the serum of
patients with colon cancer (104,105,106). Distinct
isoenzymes of galactosyl transferase (104,106) and of
/3-hexosaminidase (107) have been described recently.
Collagenase (68,108) and acid hydrolases (109) have
been shown increased in tumor tissue (table 10). On
the other hand, a decrease of acid phosphatase and of
α-naphthyl-acetyl-esterase was found (110).
At present, enzyme determinations in serum seem to be
of little use for the timely diagnosis of colorectal malig-
nancies. This is also true with the Regan variant of al-
kaline phosphatase (111,112) and for the excretion of
arylsulfatase B in urine (113,114).
Tab. 9. Glycosyltransferase activity in homogenates of normal
and malignant human colon epithelium (from LaMont &
Isselbacher (103)) Endogenous activity refers to incorpora-
tion into glycoprotein acceptors present in the homogenate
and has been subtracted from the activity in exogenous
acceptors.
Tab. 10. Glycosidase, acid phosphatase, and protease activity in
normal mucosa and colorectal carcinomas (from Bos·
mann & Hall (109)). Values in italics: P < 0.05.
Enzyme
Galactosyltransferase:
Endogenous
Sialic acid, galactose-
free fetuin
Fucosyltransferase:
Endogenous
Sialic acid-free α ι -acid
„glycoprotein
Sialyltransferase:
Endogenous
Sialic acid-free fetuin
yV-acetylglucosaminyl-
transferase:
Endogenous
Mannosyltransferase:
Endogenous
Monosaccharide transferred
(pmol/30 min · mg protein)
Normal
67
1068
118
713
3
29
30
Carcinoma
78
526
126
1 3 2 ' *
1
27
0-Galactosidase (3.2.1.23)
arFucosidase (3.2.1.-)
0-N-Acety Igala cto saminidase
(3.2.1.-)
0-N-Acetylglu co saminidase
(3.2.1.30)
a-Mannosidase (3.2.1.24)
Acid phosphatase (3.2.3.2)
Neuraminidase (3.2.1.18)
Protease, pH 3.4 (3.4.4.9)
Protease, pH 7.4 (3.4.4.4)
Normal
(nmol/h · mg
protein)
(x ± s*)
(n)
108 ± 35 (6)
1± K6)
223 ± 64 (6)
41 3 ±98 (6)
42 ±13 (6)
343 ± 54 (5)
103 ± 41 (6)
489 ± 68 (5)
164 ± 65 (6)
Tumor
(nmol/h · mg
protein)
(x ± 8χ)
(n)
236 ± 41(7)
1 ± 1 (7)
317 ± 42(7)
355 ± 41 (7)
116 ± 23(7)
340 ± 37(6)
303 ± 41 (7)
1 399 ± 418 (7)
• 211 ±107(7)
There is still a controversy about the value, of enzyme
determinations in serum for monitoring the course of
eolorectal cancer and for the early detection of liver
.metastases. The conclusion to which the individual in-
vestigators come, depends largely on the number of en-
zymes measured, and still more on the care bestowed upon
the interpretation of the results. Thus, those who meas-
ure only one enzyme or count only "positives" arid
"negatives", feel that they cannot rely on their findings,
especially because of the high rate of "false^positives"
(115—121). This is demonstrated in table 11 and has
been amply discussed by Read (121). There are, how-
Tab. 11. Diagnostic value of the determination of alkaline phos-
phatase and lactate dehydrogenase in colorectal cancer
(from Read et al. (121)).
Number Number
of Cases Elevated
Series
Alkaline Phosphatase
Gennaro & 146 -
Bacon
Almersjo 90 67
etal.
Ranson 117 6
etal.
Fee et al. 70 40
Ariel & 22 2
Shahon
G6///rtetal. 125 82
Guitierrez
etal. 106 14
Present 123 34
series*
Lactate Dehydrogenase
Ranson etal. 113 23
Gottin et a]L 67 37
Present 118 30
series*
Correct
values
(%)
78
85
63
64
76
93
78
91
60
78'
False-
negative
values
e»
15
52
15
13
36
56
3
9
4
83
13.
False-
positive
values
<%)
18
12
17
56
0
7
29
56
26
5
50
* Present series = Read et al, (121); for the other references
given see I.e. (121).
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Tab. 12. Enzyme pattern in serum characteristic for liver meta-
stasesof gastro-intestinal carcinomas (from I.e. (127-
130)). " ^
Aminotransferases: slight - moderate increase:
(aspartate: GOT; alanine: GPT) GOT/GPT > 1.0
Glutamic dehydiogenase (GLDH):slight - marked increase:
GPT/GLDH < 10
Alkaline phosphatase:
•γ-Glutamyl transferase (γ-GT):
Lactate dehydrogenase (LDH):
Cholinesterase:
slight - marked increase:
moderate - marked increase:
7-GT/GOT>1.0
slight - moderate increase:
HBDH*/LDH = normal
slight - marked reduction:
20-60 %
:
 HBDH = hydroxybutyrate dehydrogenase
ever, also positive voters, who consider enzyme determi-
nations suitable as screening methods (122-126). In our
experience the pattern outlined in table 12 has stood
the test in routine examinations for more than a decade
in disclosing and discriminating hepatic metastases to
the extent of more than 80 % (127-130).
At the end of this chapter an interesting preliminary
study ofSykes et al. may be mentioned: From 18 cases
of human colorectal carcinoma they found in 10 cases
high, and in 8 cases low Superoxide dismutase .activity
(131). As it has been shown that tissues with a high
activity of this enzyme are resistent to ionizing irradiation
and vice versa (132), possible radiation sensitivity of
tumors can be predicted and moreover, by inhibition of
high Superoxide dismutase activity, might be enhanced.
Side Effects of Therapy
It is self-evident that cytostatic drugs affect a tissue which
proliferates as fast as intestinal epithelium. The disac-
charidases are the best investigated enzymes in this
respect. Their activity decreases faster than would be
expected by a pure antimitotic effect upon the crypt cells;
therefore, a direct toxic action on the brush border
membranes with release of the respective enzymes must
also be taken into consideration (table 13; 133-143).
Tab. 13. Effects of cytostatic drugs on brush border enzymes of rat intestine (from Ecknauer & Rommel (133)) I = decreased;
t = increased; = unchanged.
Cytostatic Drug
Aminopterine
Colchicine
Cyclophosphamide
5-Fluorouracil
Vincristin
MA = MaJtase; SA =
transf erase.
Dose (mg/kg)
1 X 1.2
7 X 0 . 2
1 X 1.0
3 X 1.0
1 X 1.0
1 X 100
1 X40
1 X 250
I X 375
1 X 0.1
Saccharase; LA = Lactase; CA
Enzyme
alteration
SA/LA
MA
SA
MA
ALP
MA/SA/LA
ALP/7-GT
MA/TA/LA/CA
MA/SA/LA/CA
ALP/SA
SA/MA
Time (h)
;
I
\
it
\r
= 24+48
= 6+12
;
U
tt 24
U 72
4
= Cellobiase; TA = Trehalase; ALP
Author(s)* Year
Wolff, 1967
ScA/ra/rf/etal. 1961
Herbst etal. 1970
Herbst el *\. 1970
Fredericson et al. 1956
Ecknauer et al. 1976
Mielcke, 1975
Hartwich etal. 1974
Bounous 1971
Hartwich etal. 1976
= Alkaline Phosphatase; -y-GT - r-Glutamyl-
*for complete references see i.e. (133)
Tab. 14. Effect of various drugs on the activity of alkaline phosphatase* in human feces (from (Frolkis et al. (145))
Drug.**
Chlpramphenicol
Qleandomycin
Tetracycline
Furazolidone
Halquinol/Phanquone
Sulfagiiamdine
Salazosulfapyridine
Furosemide
Toibutamide
* Arbitrary Units/g feces (Normal range 45-420 AU/g)
** Drugs given in therapeutical doses for 7-8 days.
Before treatment
14
10
13
10
11
7
10
5
7
273 ±
422 ±
329 ±
286 ±
583 ±
460 ±
550 ±
323 ±
83 ±
36.6
29.7
43.0
58.0
108
157
76.0
147
13.0
P
< 0.001
< 0.001
< 0.001
<0.01
n.s.
<0.02
n.s.
n.s.
n.s.
After treatment
936 ± 90.5
1048 ± 78.3
1021 ±71.0
598 ± 49.0
561 ± 83.0
1160 ±151
472 ± 64.0
391 ± 188
102 ±10.0
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Another group of drugs which is well known to affect
structure and function of intestinal mucosa is that of
antibiotics and other antibacterial substances. Several
antibiotics - especially neomycin - lead to severe villous
atrophy as a consequence of their inhibition of protein
synthesis and their impairment of selective membrane
permeability (144). Whether the elevated activity of
alkaline phosphatase and of other enzymes in the feces
after the administration of some antibiotics is due to a
higher release from damaged cells or to a diminished
degradation by the reduced microflora of the gut (table
14; 145), is still under discussion.
Another aspect is that bacterial overgrowth has been
blamed for many manifestations in the blind loop
^250 -
pre post
30 -
20
10
(10)
(49)
(37)
/AS//////////////////////////////////
J I I
pre post 6
t (mon th )
12
Fig. 9. Enzyme activity in serum before and after jejuno-ileal
bypass for morbid obesity. The bars give means ± range.
From Spin & Weismann (146).
syndromes (154), and that its role together with the
stasis of the secretions in the long excluded bowel
segment has been emphasized by some of the authors
(147,148) who report liver damage after jejuno-ileal
bypass for massive obesity (146-150). Figure 9 shows
that liver parenchymal cell damage is common there-
after, but of variable degree. As a rule, it is not the
fatty liver of the malnourished that is found, but a
toxic injury resembling alcoholic hepatitis.
The intestine itself seems to compensate within weeks
to months to its altered function, as it is shown in
figure 10 by the example of alkaline phosphatase (153).
While in the excluded, non^functioning long segment
most enzyme activities decrease, in both short func-
tioning segments there are increases up to 4 times which
are more marked in the ileum than in the jejunum. This
is, in an extreme artificial situation, further proof for the
enormous capacity of adaptation of the gut enzymes,
which makes the differentiation between cause and
effect in bowel enzymology so difficult.
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Fig. 10. Specific activities of alkaline phosphatase (U/g protein).
Mean enzyme activity of each segment is given as a bar.
Preoperative specimens: jejunal control (JC) and ileal
control (1C). Postoperative specimens: jejunal included
segment (JIS), jejunal excluded segment (JES), ileal
included segment (IIS), ileal excluded segment (IBS).
From Stein & Wise (153).
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